Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study

Jesús Troya, Pablo Ryan, Esteban Ribera, Daniel Podzamczer, Victor Hontañón, Jose Alberto Terrón, Vicente Boix, Santiago Moreno, Pilar Barrufet, Manuel Castaño, Ana Carrero, Marõa José Galindo, Ignacio Suárez-Lozano, Hernando Knobel, Miguel Raffo, Javier Solõs, Marõa Yllescas, Herminia Esteban, Juan González-Garcõa, Juan BerenguerArkaitz Imaz

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds

Agriculture & Biology